Defending Access to Medicines in Trade
Due to the lobbying power of individual wealthy countries and the influence of the industry on those countries' policymakers, international trade deals are often used as place to expand monopoly protections for the pharmaceutical industry and create other detrimental intellectual property (IP) policies at the behest of powerful corporate interests. These policies create barriers for generic market competition, keeping medicines prices high around the world, and deny people basic access to knowledge, shaping the knowledge economy according to the interests of powerful corporations instead of everyday people. Public Citizen works against the negative effects of these trade deals, and the Access to Medicines and Knowledge Economy Group works to combat over-reaching IP protections and enforcement rules that harm the public interest.
A trade agreement between the ten members of the Association of Southeast Asian Nations (ASEAN) and six states that have active trade agreements with ASEAN. Download our report on data exclusivity provisions that would undermine access to affordable medicines and provide unchecked monopoly power in the agreement.
The U.S. Trade Representative tried to pressure developing countries to trade away access to medicines in the proposed Trans-Pacific Partnership (TPP) Agreement. Public Citizen worked to preserver access to affordable medicines by pushing back against harmful proposed rules in the TPP until the agreement was defeated.
The U.S. and EU are seeking to establish a new "gold standard" for IP rules which, over time, developing countries will most likely be pressed to adopt. Public Citizen is working with U.S. and EU allies to tell negotiators to keep IP out of any EU-U.S. trade agreement.
Global Trade Watch's mission is to ensure that in this era of globalization, a majority have the opportunity to enjoy economic security, a clean environment, safe food, medicines and products, access to quality affordable services such as health care and the exercise of democratic decision-making about the matters that affect their lives.
The U.S. government maintains a list of priority countries that are "bad actors" in trade. Oftentimes this designation is awarded for public-interest focused policies on intellectual property. Public Citizen watches this list and defends countries who are categorized unfairly.
A historic record on the work of Public Citizen's Access to Medicines Program on medicine quality and counterfeit policy.